Trials / Completed
CompletedNCT00467779
Study of Cobimetinib in Participants With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cobimetinib | Repeating oral dose |
| DRUG | dextromethorphan | In Stage III only: single dose of dextromethorphan |
| DRUG | midazolam | In Stage III only: single dose of midazolam |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2007-05-01
- Last updated
- 2016-08-26
- Results posted
- 2016-07-22
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00467779. Inclusion in this directory is not an endorsement.